Insulin delivery systems: Present trends and the future direction

Indian Journal of Pharmacology

Volumn 34, Issue 6, 2002, Pages 379-389

  Tyagi, Pradeep ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Diabetes; Inhalation; Insulin delivery systems; Insulin pump; Stem cell

Indexed keywords

1 VINYL 2 PYRROLIDINONE; 3 SULFOPROPYL ACRYLIC ACID; ACRYLAMIDE; BOVINE INSULIN; CONCANAVALIN A; GLUCOSE; GLUCOSE OXIDASE; INSULIN; INSULIN DERIVATIVE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; MACROGOL; MONOMER; N,N DIMETHYLAMINOETHYL METHACRYLATE POLYMER; POLYMACON; POLYMER; POTASSIUM SALT; TETRAETHYLENE GLYCOL DIMETHACRYLATE POLYMER; UNCLASSIFIED DRUG;

ARTIFICIAL PANCREAS; ATHEROSCLEROSIS; CLINICAL TRIAL; COMMON COLD; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MEGADOSE; DRUG MIXTURE; DRUG TISSUE LEVEL; DRUG USE; FORECASTING; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HUMAN; HYDROGEL; HYPERINSULINEMIA; INHALER; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN PUMP; INSULIN TREATMENT; MEDICAL LITERATURE; MEDICAL RESEARCH; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOSE CONGESTION; NOSE IRRITATION; PANCREAS TRANSPLANTATION; REVIEW; RHINORRHEA; SENSOR; SEPSIS; SIDE EFFECT; STEM CELL; THROMBOSIS; WEIGHT GAIN;

EID: 0036900745     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Hildebrandt P, Birch K. Basal rate subcutaneous insulin infusion: Absorption kinetics and relation to local blood flow. Diabet Med 1988;5:434-40.
2. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998;21:1910-4.
3. Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am 2001;30:935-82.
4. DCCT Research Group. Diabetes Control and Complications Trial (DCCT): The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
6. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC): Design, implementation and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99-111.
7. Rosenstock J. Insulin therapy: Optimizing control in type 1 and type 2 diabetes. Clin Cornerstone 2001;4:50-64.
8. Bolli GB. Physiological insulin replacement in type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 2001;109(Suppl 2):317-32.
9. Duckworth WC, Saudek CD, Henry RR. Why intraperitoneal delivery of insulin with implantable pumps in NIDDM? Diabetes 1992;41:657-61.
10. Laville M, Andreelli F. Mechanisms for weight gain during blood glucose normalization. Diabetes Metab 2000;26(Suppl 3):42-5.
11. Steil GM, Rebrin K, Mittelman SD, Bergman RN. Role of portal insulin delivery in the disappearance of intravenous glucose and assessment of insulin sensitivity. Diabetes 1998;47:714-20.
12. Jeandidier N, Boullu S, Delatte E, Sapin R, Steibel J, Meyer P, Uhl C, Pinget M. High antigenicity of intraperitoneal insulin infusion via implantable devices: Preliminary rat studies. Horm Metab Res 2001;33:34-8.
13. Selam JL, Medlej R, M'Bemba J. Symptoms, hormones and glucose fluxes during a gradual hypoglycaemia induced by intraperitoneal vs venous insulin infusion in type 1 diabetes. Diabet Med 1995;12:1102-9.
14. Selam JL, Charles MA. Devices for insulin administration. Diabetes Care 1990;13:955-79.
15. Teutsch SM, Herman WH, Dwyer DM. Mortality among diabetic patients using continuous subcutaneous insulin-infusion pumps. N Engl J Med 1984;310:361-8.
16. Simmons D, Thompson CF, Conroy C, Scott DJ. Use of insulin pumps in pregnancies complicated by type 2 diabetes and gestational diabetes in a multiethnic community. Diabetes Care 2001;24:2078-82.
17. Maniatis AK, Klingensmith GJ, Slover RH, Mowry CJ, Chase HP. Continuous subcutaneous insulin infusion therapy for children and adolescents: An option for routine diabetes care. Pediatrics 2001;107:351-6.
18. Duckworth WC, Saudek CD, Giobbie-Hurder A, Henderson WG, Henry RR, Kelley DE, et al. The Veterans Affairs Implantable Insulin Pump Study: Effect on cardiovascular risk factors. Diabetes Care 1998;21:1596-602.
19. Ruotolo G, Parlavecchia M, Taskinen MR, Galimberti G, Zoppo A, Le NA, et al. Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activity. Diabetes Care 1994;17:6-12.
20. Selam JL. External and implantable insulin pumps: Current place in the treatment of diabetes. Exp Clin Endocrinol Diabetes 2001;109(Suppl 2):333-40.
21. Rizvi AA, Petry R, Arnold MB, Chakraborty M. Beneficial effects of continuous subcutaneous insulin infusion in older patients with long-standing type 1 diabetes. Endocr Pract 2001;7:364-9.
22. Raskin P, Holcombe JH, Tamborlane WV, Malone JI, Strowig S, Ahern JA, Lavent F. A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. J Diabetes Complications 2001;15:295-300.
23. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: Evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002;25:593-8.
24. Thompson JS, Duckworth WC. Insulin pumps and glucose regulation. World J Surg 2001;25:523-6.
25. Thompson JS, Duckworth WC, Saudek CD, Giobbie-Hurder A. Surgical experience with implantable insulin pumps. Department of Veterans Affairs Implantable Insulin Pump Study Group. Am J Surg 1998;176:622-6.
26. Kessler L, Tritschler S, Bohbot A, Sigrist S, Karsten V, Boivin S, et al. Macrophage activation in type 1 diabetic patients with catheter obstruction during peritoneal insulin delivery with an implantable pump. Diabetes Care 2001;24:302-7.
27. Catargi B, Breilh D, Gin H, Rigalleau V, Saux MC, Roger P, et al. A randomized study comparing blood glucose control and risk of severe hypoglycemia achieved by non-programmable versus programmable external insulin pumps. Diabetes Metab 2001;27:323-7.
28. Kim JJ, Park K. Modulated insulin delivery from glucose-sensitive hydrogel dosage forms. J Control Release 2001;77:39-47.
29. Traitel T, Cohen Y, Kost J. Characterization of glucose-sensitive insulin release systems in simulated in vivo conditions. Biomaterials 2001;21:1679-87.
30. Bendayan M, Ziv E, Gingras D. Biochemical and morphocytochemical evidence for intestinal absorption of insulin in control and diabetic rats, comparison between the effectiveness of duodenal and colon mucosa. Diabetologia 1994;37:119-126.
31. Adibi SA. The oligopeptide transporter (Pept-1) in human intestine: Biology and function. Gastroenterology 1997;113:332-40.
32. Ma XY, Pan GM, Lu Z, Hu JS, Bei JZ, Jia JH, et al. Preliminary study of oral polylactide microcapsulated insulin in vitro and in vivo. Diabetes Obes Metab 2000;2:243-50.
33. Ramadas M, Paul W, Dileep KJ, Anitha Y, Sharma CP. Lipoinsulin encapsulated alginate-chitosan capsules: Intestinal delivery in diabetic rats. J Microencapsul 2000;17:405-11.
34. Musabayane CT, Munjeri O, Bwititi P, Osim EE. Orally administered, insulin-loaded amidated pectin hydrogel beads sustain plasma concentrations of insulin in streptozotocin-diabetic rats. J Endocrinol 2000;164:1-6.
35. Tell JT. Gastrointestinal transit of microcapsules. In: Ponbrow, M ed. Microcapsules and Nanoparticles in Medicine and Pharmacy. Boca Raton: CRC Press; 1992.
36. Singh M, Singh A, Talwar GP. Controlled delivery of diphtheria toxoid using biodegradable poly (O, L-Lactide) microcapsules. Pharmacol Res 1991;8:958-61.
37. Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001;2:198-209.
38. Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: A randomized controlled trial. Diabetes Care 2001;24:1556-9.
39. Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: A randomised proof-of-concept study. Lancet 2001;357:331-5.
40. Gill GV. Viewpoint: Stability of insulin in tropical countries. Trop Med Int Health 2000;5:666-7.
41. Heinemann L, Pfutzner A, Heise T. Alternative routes of administration as an approach to improve insulin therapy: Update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des 2001;7:1327-51.
42. Prausnitz MR. Overcoming skin's barrier: The search for effective and user-friendly drug delivery. Diabetes Technol Ther 2001;3:233-6.
43. Zakzewski CA, Wasilewski J, Cawley P, Ford W. Transdermal delivery of regular insulin to chronic diabetic rats: Effect of skin preparation and electrical enhancement. J Control Release 1998;50:267-72.
44. Boucaud A, Garrigue MA, Machet L, Vaillant L, Patat F. Effect of sonication parameters on transdermal delivery of insulin to hairless rats. J Control Release 2002;81:113-9.
45. Brand RM, Hannah TL, Hamel FG. A combination of iontophoresis and the chelating agent 1, 10 phenanthroline act synergistically as penetration enhances. AAPS Pharm Sci 2000;2:35.
46. Meyer BR, Katzeff HL, Eschbach JC, Trimmer J, Zacharias SB, et al. Transdermal delivery of human insulin to albino rabbits using electrical current. Am J Med Sci 1989;297:321-5.
47. Kanikkannan N, Singh J, Romarao P. Transdermal iontophoretic delivery of bovine insulin and monomeric human insulin analogue. J Control Release 1999;59:99-105.
48. Choi EH, Lee SH, Ahn SK, Hwang SM. The pretreatment effect of chemical skin penetration enhancers in transdermal drug delivery using iontophoresis. Skin Pharmacol Appl Skin Physiol 1999;12:326-35.
49. Morgan RV. Delivery of systemic regular insulin via the ocular route in cats. J Ocul Pharmacol Ther 1995;11:565-73.
50. Ritchel WA, Ritschel GB, Ritschel BE, Lucker PW. Rectal delivery system for insulin. Method Find Exp Clin Pharmacol Method Find Exp Clin Pharmacol 1988;10:645-56.
51. Yamasaki Y, Shichiri M, Kawamori R, Kikuchi M, Yagi T, Arai S, et al. The effectiveness of rectal administration of insulin suppository on normal and diabetic subjects. Diabetes Care 1981;4:454-8.
52. Sutherland DE, Gruessner RW, Gruessner AC. Pancreas transplantation for treatment of diabetes mellitus. World J Surg 2001;25:487-96.
53. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230-8.
54. Ohgawara H. Strategies for immunoisolation in islet transplantation: Challenges for the twenty-first century. J Hepatobiliary Pancreat Surg 2000;7:374-9.
55. Sambanis A. Engineering challenges in the development of an encapsulated cell system for treatment of type 1 diabetes. Diabetes Technol Ther 2000;2:81-9.
56. Duvivier-Kali VF, Omer A, Parent RJ, O'Neill JJ, Weir GC. Complete protection of islets against allorejection and autoimmunity by a simple barium-alginate membrane. Diabetes 2001;50:1698-705.
57. King A, Sandler S, Andersson A. The effect of host factors and capsule composition on the cellular overgrowth on implanted alginate capsules. J Biomed Mater Res. 2001;57:374-83.
58. Lanza RP, Jackson R, Sullivan A, Ringeling J, McGrath C, Kuhtreiber W, et al. Xenotransplantation of cells using biodegradable microcapsules. Transplantation 1999;67:1105-11.
59. Soria B, Skoudy A, Martin F. From stem cells to beta cells: New strategies in cell therapy of diabetes mellitus. Diabetologia 2001;44:407-15.
60. Ramiya VK, Maraist M, Arfors KE, Schatz DA, Peck AB, Cornelius JG. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. Nat Med 2000;6:278-82.
61. Weir GC, Bonner-Weir S. Scientific and political impediments to successful islet transplantation. Diabetes 1997;46:1247-56.
62. Udipi K, Ornberg RL, Thurmond KB II, Settle SL, Forster D, Riley D. Modification of inflammatory response to implanted biomedical materials in vivo by surface bound superoxide dismutase mimics. J Biomed Mater Res 2000;51:549-60.
63. Klinge U, Klostherhalfen B, Birkenhauer V, Junge K, Conze J, Schumpelick V. Impact of polymer pore size on the interface scar formation in a rat model. J Surg Res 2002;103:208-14.
64. Ingatius AA, Betz O, Augat P, Claes LE. In vivo investigations on composites made of resorbable ceramics and poly(lactide) used as bone graft substitutes. J Biomed Mater Res 2001;58:701-9.
65. Brauker JH, Carr-Brendel VE, Martinson LA, Crudele J, Johnston WD. Neovascularization of synthetic membranes directed by membrane microarchitecture. J Biomed Med Res 1995;29:1517-24.
66. Mikos AG, Sarakinos G, Lyman MD, Ingber DE, Vacanti JP, Langer R. Prevascularization of porous biodegradable polymers. Biotech Bioengng 1993;42:716.